Losartan Effect on lowering TNF-α Serum Levels in Asymptomatic Hyperuricemia Hypertension Patients

Abstract

Hypertension has strong association with hyperuricemia. The serum uric acid levels were elevated in 25% untreated hypertensive subjects. 30% of hypertensive patients were hyperuricemic and gouty arhtritis. Hypertension and hyperuricemia are two conditions that might increases risk factor for CV events such as obesity, dyslipidemia, insulin resistances, metabolic syndrome. Hyperuricemia is a condition can cause a systemic inflammation leading to endothelial dysfunction. TNF-α is one of marker systemic inflammation, The purpose of this study was to determine the effect of losartan on levels of TNF-α Serum in hypertensive patients with asymptomatic hyperuricemia disease This was a before-after study design, conducted in Departement of Internal Medicine, Mohammad Hoesin Hospital (RSMH) Palembang began in March until August 2013. Subjects included were 30 patients (53,3% male). The effect of losartan on systolic and diastolic blood pressure were 146,00 ± 4,98 to 88,67 ± 3,45 mmHg and 126,67 ± 7,39 to 79,00 ± 4,02 mmHg respectively (p = 0,000). The levels of serum TNF-α before and after administration of losartan were 9,39 ± 1,05 pg/ml and 3,29 ± 2,26 pg/ml and statistically significant different with p < 0,000. This study proved the effect of losartan on the decreased TNF-α Serum.